|
| Press Releases |
|
 |
|
| Wednesday, March 31, 2021 |
|
|
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan |
| Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., (known as MSD outside the United States and Canada) announced today that Eisai has submitted an application in Japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA. more info >> |
|
| Tuesday, March 30, 2021 |
|
|
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab |
| Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate, in combination with anti-PD-1 therapy pembrolizumab. more info >> |
|
|
エーザイ、抗がん剤レンバチニブについてペムブロリズマブとの併用療法における進行性腎細胞がんおよび進行性子宮内膜がんに係る2つの適応追加申請が欧州医薬品庁により受理 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）は、このたび、自社創製の抗がん剤レンバチニブメシル酸塩（製品名：「レンビマ(R)」、「Kisplyx(R)」、以下 レンバチニブ）について、Merck & Co., Inc. Kenilworth, N.J., U.S.A.（北米以外ではMSD）の抗PD-1抗体ペムブロリズマブ（製品名：「キイトルーダ(R)」、以下 ペムブロリズマブ）との併用療法における進行性腎細胞がんおよび進行性子宮内膜がんに係る適応追加の申請をそれぞれ行い、欧州医薬品庁によって受理されましたのでお知らせします。 more info >> |
|
| Friday, March 26, 2021 |
|
|
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021 |
| Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel, the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ. more info >> |
|
| Tuesday, March 23, 2021 |
|
|
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan |
| Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma. more info >> |
|
|
エーザイとMSD、「レンビマ(R)」（レンバチニブ）について日本において「切除不能な胸腺癌」の効能効果の承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）とMerck & Co., Inc., Kenilworth, N.J., U.S.A.の日本法人であるMSD株式会社（本社：東京都千代田区、代表取締役社長： カイル・タトル、以下 MSD）は、本日、エーザイ創製のマルチキナーゼ阻害剤「レンビマ(R)」（一般名：レンバチニブメシル酸塩）について、日本において「切除不能な胸腺癌」の効能効果追加の承認を取得したことをお知らせします。本剤は、日本における「切除不能な胸腺癌」に対する初めての承認薬剤となります。 more info >> |
|
| Monday, March 22, 2021 |
|
|
エーザイ、川島工園において新注射剤棟/研究棟新築工事に着工 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、本日、当社の中期経営計画EWAY2025実現に向けた戦略投資の一環として、川島工園（岐阜県）において、新注射剤棟/研究棟（名称：Eisai Medicine Innovation Technology Solutions、以下 EMITS）建設の起工式を実施したことをお知らせします。 more info >> |
|
|
Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan |
| Eisai Co., Ltd. announced today that, as part of one strategic investment towards the realization of its medium-term business plan "EWAY2025", it has conducted the groundbreaking ceremony for the construction of a new injection/research building "Eisai Medicine Innovation Technology Solutions" ("EMITS") at the Kawashima Industrial Park located in Gifu Prefecture, Japan. more info >> |
|
|
エーザイ、「新・ダイバーシティ経営企業 100 選」を受賞 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、本日、経済産業省が主催する「新・ダイバーシティ経営企業 100 選」（経済産業大臣表彰）を受賞しましたのでお知らせします。当社は、今回が初の受賞となります。 more info >> |
|
|
Eisai Awarded The New Diversity Management Selection 100 |
| Eisai Co., Ltd. announced today that it was selected as one of winners of the Ministry of Economy, Trade and Industry (METI) Minister's Award of the New Diversity Management Selection 100 by METI. This marks the first time to be awarded ever since Eisai was included in the New Diversity Management Selection 100 Program. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Datavault AI Inc.（纳斯达克代码：DVLT）宣布2026年第一季度签署了总值7.5亿美元的代币化合约，产生相关费用7700万美元
Apr 8, 2026 22:35 HKT/SGT
|
|
|
Datavault AI Inc. (NASDAQ: DVLT) Announces $750 Million in Tokenization Contracts Signed in Q1 2026, Generating $77 Million in Associated Fees
Apr 8, 2026 22:35 HKT/SGT
|
|
|
Mobile Charging Industry Report: When "Piles" Start "Walking", Who Defines the New Rules of Energy Rescue?
Apr 8, 2026 22:30: JST
|
|
|
Founders Metals Announces Increased Strategic Investment by Gold Fields
Apr 8, 2026 22:29 HKT/SGT
|
|
|
Droid Investment Funds Launches 'The 10 Fund Competition Institutional Capital vs. The Wisdom of the Crowd'
Apr 8, 2026 22:15: JST
|
|
|
Mobile Charging Industry Report: When "Piles" Start "Walking", Who Defines the New Rules of Energy Rescue?
Apr 8, 2026 21:30 HKT/SGT
|
|
|
移动充电行业深度研报：当"桩"开始"走路"，谁在定义能源救援的新规则？
Apr 8, 2026 21:30 HKT/SGT
|
|
|
Military Metals Reports Maiden Inferred Resource Estimate Containing 67,000 Tonnes of Antimony and 222,000 Ounces of Gold at Flagship Trojarova Project, Europe
Apr 8, 2026 21:29 HKT/SGT
|
|
|
Mitsubishi Motors Launches the Xforce in Malaysia
Apr 8, 2026 20:47 JST
|
|
|
海通恆信經營韌性持續增強 融資創新與綠色金融雙向突破
Apr 8, 2026 18:47 HKT/SGT
|
|
|
海通恒信经营韧性持续增强 融资创新与绿色金融双向突破
Apr 8, 2026 18:47 HKT/SGT
|
|
|
Droid Investment Funds Launches 'The 10 Fund Competition Institutional Capital vs. The Wisdom of the Crowd'
Apr 8, 2026 17:38 HKT/SGT
|
|
|
Guoyuan International: Essex Bio-Technology Embarks on Global Expansion, Maintains BUY Rating with Target Price of HK$6.84
Apr 8, 2026 17:20 HKT/SGT
|
|
|
Alpix Shares Early Beta Insights on AI-Assisted Trading and On-Chain Perpetuals Platform
Apr 8, 2026 15:30: JST
|
|
|
Alpix Shares Early Beta Insights on AI-Assisted Trading and On-Chain Perpetuals Platform
Apr 8, 2026 15:30 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
